Hengrui Medicine's remazolam tosylate for injection received the notice of drug supplement application approval

On September 27, Hengrui Pharmaceuticals issued an announcement stating that the company received the approval of the State Food and Drug Administration for the "Drug Supplementary Application Approval Notice" for remazolam tosylate for injection, in the 36mg specification that has been approved for marketing [ On the basis of remazolam {C21H19BrN4O2}], a new 25mg specification [calculated as remazolam {C21H19BrN4O2}] is added

In December 2019, the company's 36mg remazolam tosylate for injection [calculated as remazolam {C21H19BrN4O2}] was approved by the National Food and Drug Administration for routine gastroscopy sedation; it was approved for use in June 2020 Sedation of colonoscopy

Remazolam tosylate belongs to the class of benzodiazepines and is a short-acting GABAa receptor agonist

Remazolam besylate developed by PAIONAG, Germany, was approved for general anesthesia in Japan in January 2020, approved for procedural sedation in the United States in July 2020, and approved for listing in China in July 2020 Used for sedation during colonoscopy

Up to now, the total R&D expenses of remazolam tosylate for injection have been about 108.